Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2009)
15 slides from Resonance Health's shareholder meeting presentation, Nov 25, 2009
Slide 1: Annual General Meeting
For personal use only Resonance Health Ltd ACN 006 762 492 Annual General Meeting 25 November 2009
Slide 2: Highlights for the Year
Resonance Health Ltd (RHT) Highlights for the Year For personal use only • First full financial year profit reported • Growth in volume and revenue for FerriScan business • Gained reimbursement for FerriScan in several markets • Opened sales offices in UK and Germany • Started initial clinical trial
Slide 3: Resonance Health Ltd (RHT)
Resonance Health Ltd (RHT) • ASX Listed, HQ in Perth – staff of 13 For personal use only • Provide radiology image analysis services to the international pharmaceutical and clinical communities • Develop and utilise unique patented image analysis technology, providing non-invasive imaging alternativ
Slide 4: Iron Overload Market
Iron Overload Market For personal use only FerriScan replaces the liver biopsy test for the accurate assessment of iron overload, providing an accurate and safe alternative Hereditary Haemochromatosis or Primary Iron Overload – Over 2 million cases in USA & Europe – 1 in 250 people from Northern Eur
Slide 5: Liver Iron and Risks
Liver Iron and Risks only Hepatic iron, mg/g of liver, dry weight Iron (µmol/g wet weight) Thalassaemia major: 50 250 transfusion without chelation Homozygous use haemochromatosis 40 200 Heterozygote 30 personal 150 Threshold for cardiac 20 100 disease and early death For Hepatic Increased risk of c
Slide 6: Liver Iron Predicts Risk of Myocardial Iron
Liver Iron Predicts Risk of Myocardial Iron For personal use only 40 35 Myocardial iron (µmol/g) 30 25 20 15 10 5 0 0 100 200 300 400 500 600 700 Liver iron (µmol Fe/g) Jensen PD, et al. Blood. 2003;101:4632-9.
Slide 7: The Competition: Measuring Liver Iron by Biopsy
The Competition Measuring Liver Iron by Biopsy For personal use only
Slide 8: FerriScan - Measuring Liver Iron by Magnetic Resonance Imaging
FerriScan® - Measuring Liver Iron by Magnetic Resonance Imaging For personal use only 150 s-1 100 s-1 50 s -1 0 s-1 R2 • Map of liver iron • Accurate • Non-invasive • Repeatable
Slide 9: Global Distribution of Major Iron Overload Diseases
Global Distribution of Major Iron Overload Diseases For personal use only
Slide 10: FerriScan Locations
For personal use only FerriScan Locations
Slide 11: FerriScan Strategy
FerriScan Strategy For personal use only • Continue to expand sales presence – USA, Germany, UK & Australia • Insurance reimbursement for FerriScan – Regional success in UK and Canada – Australian decision expected Q1 2010 – US reimbursement consultants focusing on local and national insurance cover
Slide 12: Financial Results
Financial Results AUD For personal use only 2005-6 2006-7 2007-8 2008-9 FerriScan # 912 1945 1605 2200 $2,259,191 FerriScan Revenue* $313,532 $1,868,790 $1,722,085 (up 31%) Expenses $4.1m** $3.1m $2.1m $1.8m Net (Loss) A/ Tax $3.3m Loss** $725k Loss $41k Loss $617k Profit Year end Cash $0.6m $2.4m $
Slide 13: RHT Share Price and Volumes
RHT Share Price and Volumes For personal use only Average daily trading volume 98,700
Slide 14: Liver Fibrosis Measurement: A Much Larger Target Market
Liver Fibrosis Measurement A Much Larger Target Market For personal use only • Large addressable market – Independently valued at +$100m pa • Primary causes of liver fibrosis: – Viral hepatitis – 170m people world wide have Hep C (2.7m in US) – Fatty liver disease –1/3 of American adults have fatty
Slide 15: Fibrosis Measurement Technology Target Timelines
Fibrosis Measurement Technology Target Timelines For personal use only • Q4 2007 Independent market assessment completed • Q1 2010 Product feasibility completed • Q4 2010 Product development finalised in US population • Q2 2011 Product validated in US population • Q4 2011 Regulatory submission – 510
Resonance Health — Shareholder Meeting (November 2009) on 6ix